About 3-ketoacyl-CoA thiolase, peroxisomal
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1) is a protein
from Homo sapiens identified by UniProt accession
P09110, 424 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | 3-ketoacyl-CoA thiolase, peroxisomal |
| UniProt accession | P09110 |
| Gene | ACAA1 |
| Organism | Homo sapiens |
| Length | 424 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (87)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.33
- mean reticulocyte volume · score 0.17
- mean corpuscular hemoglobin concentration · score 0.08
- neoplasm · score 0.07
- non-small cell lung carcinoma · score 0.06
- cancer · score 0.05
- Red cell distribution width · score 0.05
- lung adenocarcinoma · score 0.04
- gut microbiome measurement · score 0.04
- taxonomic microbiome measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P09110-F1 | alphafold | PREDICTED | 93.96 | — |
Amino-acid sequence (424 residues)
MQRLQVVLGH LRGPADSGWM PQAAPCLSGA PQASAADVVV VHGRRTAICR AGRGGFKDTT PDELLSAVMT AVLKDVNLRP EQLGDICVGN VLQPGAGAIM ARIAQFLSDI PETVPLSTVN RQCSSGLQAV ASIAGGIRNG SYDIGMACGV ESMSLADRGN PGNITSRLME KEKARDCLIP MGITSENVAE RFGISREKQD TFALASQQKA ARAQSKGCFQ AEIVPVTTTV HDDKGTKRSI TVTQDEGIRP STTMEGLAKL KPAFKKDGST TAGNSSQVSD GAAAILLARR SKAEELGLPI LGVLRSYAVV GVPPDIMGIG PAYAIPVALQ KAGLTVSDVD IFEINEAFAS QAAYCVEKLR LPPEKVNPLG GAVALGHPLG CTGARQVITL LNELKRRGKR AYGVVSMCIG TGMGAAAVFE YPGN
Explore 3-ketoacyl-CoA thiolase, peroxisomal with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets